Neurogenetics and clinical evidence for the putative activation of the brain reward circuitry by a neuroadaptagen: Proposing an addiction candidate gene panel map

Journal of Psychoactive Drugs

Volumn 43, Issue 2, 2011, Pages 108-127

  Chen, Thomas J H ^a   Blum, Kenneth ^b,c,d,e   Chen, Amanda L C ^a   Bowirrat, Abdalla ^f   Downs, William B ^c   Madigan, Margret A ^c   Waite, Roger L ^c   Bailey, John A ^b   Kerner, Mallory ^g   Yeldandi, Swetha ^g   Majmundar, Neil ^g   Giordano, John ^h   Morse, Siohban ^e   Miller, David ⁱ   Fornari, Frank ^j   Braverman, Eric R ^h,k  

^a CHANG JUNG CHRISTIAN UNIVERSITY   (Taiwan)

^b UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^c Department of Nutrigenomics and Personalized Medicine LifeGen Inc   (United States)

^d Holistic Addiction Treatment Center   (United States)

^e National Institute of Holistic Studies   (United States)

^f Rebecca Sieff Government Hospital   (Israel)

^g Path Foundation NY   (United States)

^h Department of Nutrigenomics LifeGen Inc ^*  (United States)

ⁱ LifeStream Inc   (United States)

^j Dominion Diagnostics   (United States)

^k Hospital for Special Surgery   (United States)

more..

Author keywords

Genes; KB220 neuroadaptogen amino acid therapy (NAAT); Nutrigenomics; Polymorphisms; Reward Deficiency Syndrome(RDS)

Indexed keywords

4 AMINOBUTYRIC ACID; 5 HYDROXYTRYPTOPHAN; AMINO ACID; CHROMIUM; COCAINE; CORTICOTROPIN; DEXTRO PHENYLALANINE; DIAMORPHINE; DOCOSAHEXAENOIC ACID; DOPAMINE; DOPAMINE 2 RECEPTOR; GLUTAMINE; INTERLEUKIN 2; KB220; MEMBRANE METALLOENDOPEPTIDASE; METHYLTRANSFERASE; OPIATE; PHENYLALANINE; PLACEBO; PROENKEPHALIN; PYRIDOXINE; SALSOLINOL; SEROTONIN; TRYPTOPHAN; TUMOR NECROSIS FACTOR; TYROSINE; TYROSINE 3 MONOOXYGENASE; UNCLASSIFIED DRUG; CENTRAL STIMULANT AGENT;

ADDICTION; ALCOHOL ABUSE; ALCOHOLISM; ANGER; ANTERIOR CINGULATE; ANXIETY; ARTICLE; ATTENTION DEFICIT DISORDER; BRAIN FUNCTION; BRAIN REGION; CAUDATE NUCLEUS; COMPULSION; DISEASE ASSOCIATION; DOPAMINE METABOLISM; DOPAMINE UPTAKE; DOPAMINERGIC ACTIVITY; DRINKING BEHAVIOR; DRUG ABUSE; DRUG WITHDRAWAL; EGG; ELECTROENCEPHALOGRAM; ELECTROENCEPHALOGRAPHY; EMOTIONALITY; ENZYME INHIBITION; FUNCTIONAL MAGNETIC RESONANCE IMAGING; GENE EXPRESSION; GENE FREQUENCY; GENE INTERACTION; GENE LOCUS; GENE MAPPING; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETICS; GENOTYPE; HEALTH BEHAVIOR; HEROIN DEPENDENCE; HUMAN; HYPOTHALAMUS; IMPULSIVENESS; MESOLIMBIC DOPAMINERGIC SYSTEM; NEUROADAPTAGENAMINO ACID THERAPY; NEUROANATOMY; NEUROIMAGING; NONHUMAN; NUCLEUS ACCUMBENS; OPIATE ADDICTION; ORBITAL CORTEX; PROTEIN EXPRESSION; PUTAMEN; REWARD; RISK FACTOR; SEROTONIN RELEASE; SUBSTANCE ABUSE; THERAPY; TREATMENT OUTCOME; WELLBEING; BIOSYNTHESIS; BRAIN; BRAIN LEVEL; CHROMOSOME MAP; ENZYMOLOGY; NERVE TRACT; NUTRITIONAL SUPPORT; PATHOPHYSIOLOGY; PHYSIOLOGY; PSYCHOLOGICAL ASPECT;

ALCOHOLISM; AMINO ACIDS; BEHAVIOR, ADDICTIVE; BRAIN; BRAIN CHEMISTRY; CENTRAL NERVOUS SYSTEM STIMULANTS; CHROMOSOME MAPPING; DOPAMINE; ELECTROENCEPHALOGRAPHY; GENE FREQUENCY; NEURAL PATHWAYS; NUTRITIONAL SUPPORT; POLYMORPHISM, GENETIC; REWARD; SUBSTANCE-RELATED DISORDERS;

EID: 84855542953     PISSN: 02791072     EISSN: 21599777     Source Type: Journal    
DOI: 10.1080/02791072.2011.587393     Document Type: Article

References (104)

1. Albertson, D.N.; Schmidt, C.J.; Kapatos, G. & Bannon, M.J. 2006. Distinctive profiles of gene expression in the human nucleus accumbens associated with cocaine and heroin abuse. Neuropsychopharmacology 31 (10): 2304-12.
2. Alper, K.R.; Prichep, L.S.; Kowalik, S.; Rosenthal, M.S. & John, E.R. 1998. Persistent QEEG abnormality in crack cocaine users at 6 months of drug abstinence. Neuropsychopharmacology 19 (1): 1-9.
3. Beaver, K.M.; Wright, J.P.; Delisi, M.; Daigle, L.E.; Swatt, M.L. & Gibson, C.L. 2007 Evidence of a gene x environment interaction in the creation of victimization: Results from a longitudinal sample of adolescents. International Journal of Offender Therapy and Comparative Criminology 51 (6): 620-45.
4. Blum, K. & Kozlowski, G.P. 1990. Ethanol and Neurotransmitter Interactions: A Cascade Model of Reward. In: H. Ollat; S. Parvez; H. Parvez (Eds.) Alcohol and Behavior. Uterecht, Netherlands: VSP Press.
5. Blum, K.; Chen, A.L.C. & Chen, T.J.H. 2009. Putative targeting of dopamine D2 receptor function in reward deficiency syndrome (RDS) by Synaptamine Complex Variant (KB220): Clinical trial showing anti-anxiety effects. Gene Therapy & Molecular Biology 13: 214-30.
6. Blum, K.; Trachtenberg, M.L. & Cook, D.W. 1990. Neuronutrient effects on weight loss in carbohydrate bingers: An open clinical trial. Current Therapeutic Research 48 (2): 217-23.
7. Blum, K.; Trachtenberg, M.C. & Ramsay, J.C. 1988. Improvement of inpatient treatment of the alcoholic as a function of neurotransmitter restoration: A pilot study. International Journal of Addiction 23 (9): 991-98.
8. Blum, K.; Chen, T.J.; Morse, S.; Giordano, J.; Chaun Chen, A.L.; Thompson, J.; Allen, C.; Smolen, A.; Lubar, J.; Stice, E.; William Downs, B.; Waite, R.L.; Madigan, M.A.; Kerner, M.; Fornari, F. & Braverman, E.R. 2010a. Overcoming qEEG abnormalities and reward gene deficits during protracted abstinence in male psychostimulant and polydrug abusers utilizing putative dopamine D2 agonist therapy. Part 2. Postgraduate Medicine 122 (6): 214-26.
9. Blum, K.; Giordano, J.; Morse, S.; Liu, Y.; Tan, J.; Bowirrat, A.; Smolen, A.; Waite, R.; Downs, W; Madigan, M.; Kerner, M.; Fornari, F.; Stice, E.; Braverman, E.; Miller, D. & Bailey, J. 2010b. Genetic Addiction Risk Score (GARS) analysis: Exploratory development of polymorphic risk alleles in poly-drug addicted males. The llOAB Journal 1 (2): 1-14.
10. Blum, K.; Chen, T.J.; Downs, B.W.; Bowirrat, A.;Waite, R.L.; Braverman, E.R. Madigan, M.; Oscar-Berman, M.; DiNubile, N.; Stice, E.; Giordano, J.; Morse, S. & Gold, M. 2009a. Neurogenetics of dopaminergic receptor supersensitivity in activation of brain reward circuitry and relapse: Proposing "deprivation-amplification relapse therapy" (DART). Postgraduate Medicine 121 (6): 176-96.
11. Blum, K.; Chen, T.J.; Chen, A.L.; Madigan, M.; Downs, B.W.; Waite, R.L.; Braverman, E.R.; Kerner, M.; Bowirrat, A.; Giordano, J.; Henshaw, H. & Gold, M.S. 2009b. Do dopaminergic gene polymorphisms affect mesolimbic reward activation of music listening response? Therapeutic impact on reward deficiency syndrome (RDS). Medical Hypotheses 74 (3): 513-20.
12. Blum, K.; Chen, A.L.; Chen, T.J.; Braverman, E.R.; Reinking, J.; Blum, S.H.; Cassel, K.; Downs, B.W.; Waite, R.L.; Williams, L.; Prihoda, T.J.; Kerner, M.M.; Palomo, T.; Comings, D.E.; Tung, H.; Rhoades P. & Oscar-Berman M. 2008a. Activation instead of blocking mesolimbic dopaminergic reward circuitry is a preferred modality in the long term treatment of reward deficiency syndrome (RDS): A commentary. Theoretical Biology and Medical Modeling 5: 24.
13. Blum, K.; Chen, A.L.; Chen, T.J.; Rhoades, P.; Prihoda, T.J.; Downs, B.W.; Waite, R.L.; Williams, L.; Braverman, E.R.; Braverman, D.; Arcuri, V.; Kerner, M.; Blum, S.H. & Palomo, T. 2008b. LG839: Anti-obesity effects and polymorphic gene correlates of reward deficiency syndrome. Advances in Therapy 25 (9): 894-913.
14. Blum, K.; Chen, T.J.H.; Williams, L.; Chen, A.L.C.; Downs, B.W.; Waite, R.L.; Hutington, T.; Sims, S.; Prihoda, T.; Rhoads, P.; Reinking, J.; Braverman, D.; Kerner, M.; Blum, S.H.; Quirk, B. & Braverman, E.R. 2008c. A short term pilot open label study of LG839, a customized DNA directed nutraceutical in obesity: Exploring nutrigenomics. Gene Therapy and Molecular Biology 12: 371-82.
15. Blum, K.; Chen, T.J.H.; Chen, A.L.C.; Rhoades, P.; Prihoda, T.J.; Downs, B.W.; Bagchi, D.; Bagchi, M.; Blum, S.H.;Williams, L.; Braverman, E.R.; Kerner, M.; Waite, R.L.; Quirk, B.; White, L. & Reinking, J. 2008d. Dopamine D2 Receptor Taq A1 allele predicts treatment compliance of LG839 in a subset analysis of pilot study in the Netherlands. Gene Therapy & Molecular Biology 12: 129-40
16. Blum, K.; Chen, T.J.; Meshkin, B.;Waite, R.L.; Downs, B.W.; Blum, S.H.; Mengucci, J.F.; Arcuri, V.; Braverman, E.R. & Palomo, T. 2007a. Manipulation of catechol-O-methyl-transferase (COMT) activity to influence the attenuation of substance seeking behavior, a subtype of Reward Deficiency Syndrome (RDS), is dependent upon gene polymorphisms: A hypothesis. Medical Hypotheses 69 (5): 1054-60.
17. Blum, K.; Chen, T.J.H.; Downs, B.W.;Meshkin, B.; Blum, S.H.; Martinez Pons, M.; Mengucci, J.F.; Waite, R.L.; Arcuri, V.; Varshafski, M. & Braverman, E.R. 2007b. Synaptamine (SG8839) an amino-acid enkephalinase inhibition nutraceutical improves recovery of alcoholics, a subtype of reward deficiency syndrome (RDS). Trends in Applied Sciences Research 2 (2): 132-38.
18. Blum, K.; Chen, T.J.; Meshkin, B.; Downs, B.W.; Gordon, C.A.; Blum, S.; Mangucci, J.F.; Braverman, E.R.; Arcuri, V.; Deutsch, R. & Pons, M.M. 2007c. Genotrim, a DNA-customized nutrigenomic product, targets genetic factors of obesity: Hypothesizing a dopamineglucose correlation demonstrating reward deficiency syndrome (RDS). Medical Hypotheses 68 (4): 844-52.
19. Blum, K.; Sheridan, P.J.; Wood, R.C.; Braverman, E.R.; Chen, T.J.; Cull, J.G. & Comings, DE. 1996. The D2 dopamine receptor gene as a determinant of reward deficiency syndrome. Journal of the Royal Society of Medicine 89 (7): 396-400.
20. Blum, K.; Sheridan, P.J.; Wood, R.C.; Braverman, E.R.; Chen, T.J. & Comings, D.E. 1995. Dopamine D2 receptor gene variants: association and linkage studies in impulsive-addictive-compulsive behaviour. Pharmacogenetics 5 (3): 121-41.
21. Blum, K.; Noble, E.P.; Sheridan, P.J.; Montgomery, A.; Ritchie, T.; Jagadeeswaran, P.; Nogami, H.; Briggs, A.H. & Cohn, J.B. 1990. Allelic association of human dopamine D2 receptor gene in alcoholism. Journal of the American Medical Association 263 (15): 2055-60.
22. Blum, K.; Allison, D.; Trachtenberg, M.C.; Williams, R.W. & Loeblich, L.A. 1988a. Reduction of both drug hunger and withdrawal against advice rate of cocaine abusers in a 30 day inpatient treatment program by the neuronutrient Tropamine. Current Therapeutic Research 43: 1204-14.
23. Blum, K.; Trachtenberg, M.C.; Elliott, C.E.; Dingler, M.L.; Sexton, R.L.; Samuels, A.I. & Cataldie, L. 1988b. Enkephalinase inhibition and precursor amino acid loading improves inpatient treatment of alcohol and polydrug abusers: Double-blind placebo-controlled study of the nutritional adjunct SAAVE. Alcohol 5 (6): 481-93.
24. Blum, K.; Briggs, A.H.; Trachtenberg, M.C.; Delallo, L. & Wallace, J.E. 1987. Enkephalinase inhibition: Regulation of ethanol intake in genetically predisposed mice. Alcohol 4 (6): 449-56.
25. Blum, K.; DeLallo, L.; Briggs, A.H. & Hamilton M.G. 1982. Opioid responses of isoquinoline alkaloids (TIQs). Progress in Clinical and Biological Research 90: 387-98
26. Bowirrat, A. & Oscar-Berman, M. 2005. Relationship between dopaminergic neurotransmission, alcoholism, and reward deficiency syndrome. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics 132B (1): 29-37.
27. Brown, R.J.; Blum, K. & Trachtenberg, M.C. 1990. Neurodynamics of relapse prevention: A neuronutrient approach to outpatient DUI offenders. Journal of Psychoactive Drugs 22 (2): 173-87.
28. Chalon, S.; Delion-Vancassel, S.; Belzung, C.; Guilloteau, D.; Leguisquet, A.M.; Besnard, J.C. & Durand, G. 1998. Dietary fish oil affects monoaminergic neurotransmission and behavior in rats. Journal of Nutrition 128 (12): 2512-19.
29. Chen, A.L.C.; Blum, K.; Chen, T.J.H.; Reinking, J.; Waite, R.L.; Downs, B.W.; Braverman, E.R.; Arcuri, V.; Kerner, M.; Notaro, A.; Cassel, K.; Blum, S.H.; Bagchi, D.; Bagchi, M.; Robarge, A.; Kaats, G.; Comings, D.E.; Rhoades, P.; Williams, L. & Tung, H. 2008. The impact of biomics technology and DNA directed anti-obesity targeting of the brain reward circuitry. Gene Therapy and Molecular Biology 12: 45-68.
30. Chen, T.J.; Blum, K.; Mathews, D.; Fisher, L.; Schnautz, N.; Braverman, E.R.; Schoolfield, J.; Downs, B.W. & Comings, D.E. 2005. Are dopaminergic genes involved in a predisposition to pathological aggression? Hypothesizing the importance of "super normal controls" in psychiatricgenetic research of complex behavioral disorders. Medical Hypotheses 65 (4): 703-07.
31. Chen, T.J.; Blum, K.; Payte, J.T.; Schoolfield, J.; Hopper, D.; Stanford, M. & Braverman, E.R. 2004. Narcotic antagonists in drug dependence: Pilot study showing enhancement of compliance with SYN-10, amino-acid precursors and enkephalinase inhibition therapy. Medical Hypotheses 63 (3): 538-48.
32. Cho, S.; Ku, J.; Park, J.; Han, K.; Lee, H.; Choi, Y.K.; Jung, Y.C.; Namkoong, K.; Kim, J.J.; Kim, I.Y.; Kim, S.I. & Shen, D.F. 2008. Development and verification of an alcohol craving-induction tool using virtual reality: Craving characteristics in social pressure situation. Cyberpsychology, Behavior, and Social Networking 11 (3): 302-09.
33. Comings, D.E. & Blum, K. 2000. Reward deficiency syndrome: Genetic aspects of behavioral disorders. Progress In Brain Research 126: 325-41.
34. Crettol, S.; Besson, J.; Croquette-Krokar, M.; Hämmig, R.; Gothuey, I.; Monnat, M.; Déglon, J.J.; Preisig, M. & Eap, C.B. 2008. Association of dopamine and opioid receptor genetic polymorphisms with response to methadone maintenance treatment. Progress in Neuropsychopharmacology and Biological Psychiatry 32 (7): 1722-27.
35. Dackis, C.A. & Gold, M.S. 1985. New concepts in cocaine addiction: The dopamine depletion hypothesis. Neuroscience & Biobehavioral Reviews 9: 469-77.
36. Daunais, J.B. & McGinty, J.F. 1996. The effects of D1 or D2 dopamine receptor blockade on zif/268 and preprodynorphin gene expression in rat forebrain following a short-term cocaine binge. Brain Research and Molecular Brain Research 35 (1-2): 237-48.
37. Degenhardt, L.; Chiu, W.T.; Sampson, N.; Kessler, R.C.; Anthony, J.C.; Angermeyer, M.; Bruffaerts, R.; de Girolamo, G.; Gureje, O.; Huang, Y.; Karam, A.; Kostyuchenko, S.; Lepine, J.P.; Mora, M.E.; Neumark, Y.; Ormel, J.H.; Pinto-Meza, A.; Posada-Villa, J.; Stein, D.J.; Takeshima, T. & Wells, J.E. 2008. Toward a global view of alcohol, tobacco, cannabis, and cocaine use: Findings from the WHO World Mental Health Surveys. PLoS Medidicine 5 (7): e141.
38. Ding, Z.M.; Liu, W.; Engleman, E.A.; Rodd, Z.A. & McBride, W.J. 2009. Differential effects of dopamine D2 and GABA(A) receptor antagonists on dopamine neurons between the anterior and posterior ventral tegmental area of female Wistar rats. Pharmacology, Biochemistry and Behavior 92 (3): 404-12.
39. Downs, B.W.; Chen, A.L.; Chen, T.J.; Waite, R.L.; Braverman, E.R.; Kerner, M.; Braverman, D.; Rhoades, P.; Prihoda, T.J.; Palomo, T.; Oscar-Berman, M.; Reinking, J.; Blum, S.H.; DiNubile, N.A.; Liu, H.H. & Blum, K. 2009. Nutrigenomic targeting of carbohydrate craving behavior: Can we manage obesity and aberrant craving behaviors with neurochemical pathway manipulation by immunological compatible substances (nutrients) using a Genetic Positioning System (GPS) Map? Medical Hypotheses 73 (3): 427-34.
40. Fahrion, S.L.; Walters, E.D.; Coyne, L. & Allen, T. 1992. Alterations in EEG amplitude, personality factors, and brain electrical mapping after alpha-theta brainwave training: A controlled case study of an alcoholic in recovery. Alcoholism: Clinical and Experimental Research. 16 (3): 547-52.
41. Fernstrom, J.D. & Wurtman, R.J. 1975. Control of brain monoamine synthesis by diet and plasma amino acids. American Journal of Clinical Nutrition 28 (6): 638-47.
42. Fortuna, J.L. 2009. Nutrition for the Focused Brain. Mason, Ohio: Cengage Learning.
43. Fu, L.P.; Bi, G.H.; Zou, Z.T.; Wang, Y.; Ye, E.M.; Ma, L. & Yang, Z. 2008. Impaired response inhibition function in abstinent heroin dependents: An fMRI study. Neuroscience Letters 438 (3): 322-26.
44. George, S.R.; Roldan, L.; Lui, A. & Naranjo, C.A. 1991. Endogenous opioids are involved in the genetically determined high preference for ethanol consumption. Alcohol: Clinical and Experimental Research 15 (4): 668-72.
45. Giordano, J. & Blum, K. 2010. Probing the mysteries of recovery through nutrigenomic and holistic medicine: "Science meets recovery" through seminal translational research. Counselor Magazine 11 (5).
46. Graap, K. & Freides, D. 1998. Regarding the database for the Peniston alpha-theta EEG biofeedback protocol. Applied Psychophysiology and Biofeedback 23 (4): 265-72; 273-5.
47. Hirvonen, M.M.; Laakso, A.; Någren, K.; Rinne, J.O.; Pohjalainen, T. & Hietala, J. 2009. C957T polymorphism of dopamine D2 receptor gene affects striatal DRD2 in vivo availability by changing the receptor affinity. Synapse 63 (10): 907-12.
48. Hodgkinson, C.A.; Yuan, Q.; Xu, K.; Shen, P.H.; Heinz, E.; Lobos, E.A.; Binder, E.B.; Cubells, J.; Ehlers, C.L.; Gelernter, J.; Mann, J.; Riley, B.; Roy, A.; Tabakoff, B.; Todd, R.D.; Zhou, Z. & Goldman, D. 2008. Addictions biology: Haplotype-based analysis for 130 candidate genes on a single array. Alcohol 43 (5): 505-15.
49. Honkanen, A.; Ahtee, L. & Korpi, E.R. 1997. Voluntary alcohol drinking selectively accelerates dopamine release in the ventral striatum as reflected by 3-methoxytyramine levels. Brain Research 774 (1-2): 207-10.
50. Jelic, V.; Julin, P.; Shigeta, M.; Nordberg, A.; Lannfelt, L.; Winblad, B. & Wahlund, L.O. 1997. Apolipoprotein E epsilon4 allele decreases functional connectivity in Alzheimer's disease as measured by EEG coherence. Journal of Neurology, Neurosurgery, and Psychiatry 63 (1): 59-65.
51. Johnston, L.D.; O'Malley, P.M.; Bachman, J.G. & Schulenberg, J.E. 2009. Monitoring the Future National Results on Adolescent Drug Use: Overview of Key Findings, 2008. NIH Publication No. 09-7401. Bethesda, MD: National Institute on Drug Abuse.
52. Jonas, W. 2004. Mosby's Dictionary of Complementary and Alternative Medicine. New York: Mosby.
53. Laakso, A.; Pohjalainen, T.; Bergman, J.; Kajander, J.; Haaparanta, M.; Solin, O.; Syvälahti, E. & Hietala, J. 2005. The A1 allele of the human D2 dopamine receptor gene is associated with increased activity of striatal L-amino acid decarboxylase in healthy subjects. Pharmacogenetics and Genomics 15 (6): 387-91.
54. Lawford, B.R.; Young, R.M.; Noble, E.P.; Sargent, J.; Rowell, J.; Shadforth, S.; Zhang, X. & Ritchie, T. 2000. The D(2) dopamine receptor A(1) allele and opioid dependence: Association with heroin use and response to methadone treatment. American Journal of Medical Genetics 96 (5): 592-98.
55. Lawford, B.R.; Young, R.M.; Rowell, J.A.; Qualichefski, J.; Fletcher, B.H.; Syndulko, K.; Ritchie, T. & Noble, E.P. 1995. Bromocriptine in the treatment of alcoholics with the D2 dopamine receptor A1 allele. Nature Medicine 1 (4): 337-41.
56. Le Foll, B.; Gallo, A.; Le Strat, Y.; Lu, L. & Gorwood, P. 2009. Genetics of dopamine receptors and drug addiction: A comprehensive review. Behavioral Pharmacology 20 (1): 1-17.
57. Lee, J.; Ramchandani, V.A.; Hamazaki, K.; Engleman, E.A.; McBride, W.J.; Li, T.K. & Ki, H.Y. 2009a. A critical evaluation of influence of ethanol and diet on salsolinol enantiomers in humans and rats. Alcohol: Clinical and Experimental Research 34 (2): 242-50.
58. Lee, S.H.; Han, D.H.; Oh, S.; Lyoo, I.K.; Lee, Y.S.; Renshaw, P.F. & Lukas, S.E. 2009b. Quantitative electroencephalographic (qEEG) correlates of craving during virtual reality therapy in alcoholdependent patient. Pharmacology, Biochemistry and Behavior 91 (3): 393-97.
59. Lehtovirta, M.; Partanen, J.; Könönen, M.; Hiltunen, J.; Helisalmi, S.; Hartikainen, P.; Riekkinen, P. Sr & Soininen, H. 2000. A longitudinal quantitative EEG study of Alzheimer's disease: Relation to apolipoprotein E polymorphism. Dementia and Geriatric Cognitive Disorders 1 (1): 29-35.
60. Li, C.Y.; Mao, X. & Wei, L. 2008. Genes and (common) pathways underlying drug addiction. PLoS Computational Biology 4 (1): e2.
61. Li, D., Zhao, H. & Gelernter, J. 2011. Strong Association of the Alcohol Dehydrogenase 1B Gene (ADH1B) with Alcohol Dependence and Alcohol-Induced Medical Diseases. Biological Psychiatry. Available at http://www.ncbi.nlm.nih.gov/pubmed/21497796.
62. Li, S.X.; Shi, J.; Epstein, D.H.; Wang, X.; Zhang, X.L.; Bao, Y.P.; Zhang, D.; Zhang, X.Y.; Kosten, T.R. & Lu, L. 2009. Circadian alteration in neurobiology during 30 days of abstinence in heroin users. Biological Psychiatry 65 (10): 905-12.
63. Li, Y.; Shao, C.; Zhang, D.; Zhao, M.; Lin, L.; Yan, P.; Xie, Y.; Jiang, K. & Jin, L. 2006. The effect of dopamine D2, D5 receptor and transporter (SLC6A3) polymorphisms on the cue-elicited heroin craving in Chinese. American Journal of Medical Genetics B: Neuropsychiatric Genetics 141B (3): 269-73.
64. Liu, J.; Liang, J.; Qin, W.; Tian, J.; Yuan, K.; Bai, L.; Zhang, Y.; Wang, W.; Wang, Y.; Li, Q.; Zhao, L.; Lu, L.; von Deneen, K.M.; Liu, Y. & Gold, M.S. 2009. Dysfunctional connectivity patterns in chronic heroin users: an fMRI study. Neuroscience Letters 460 (1): 72-77.
65. Ma, N.; Liu, Y.; Li, N.; Wang, C.X.; Zhang, H.; Jiang, X.F.; Xu, H.S.; Fu, X.M.; Hu, X. & Zhang, D.R. 2010. Addiction related alteration in resting-state brain connectivity. Neuroimage 49 (1): 738-44.
66. Maldonado, R.; Daugé, V.; Feger, J. & Roques, B.P. 1990. Chronic blockade of D2 but not D1 dopamine receptors facilitates behavioural responses to endogenous enkephalins, protected by kelatorphan, administered in the accumbens in rats. Neuropharmacology 29 (3): 215-23.
67. Miller, D.; Manka, M.; Miller, M.; Stokes, S.; Allen, C.; Gant, C.; Downs, B.W.; Bowirrat, A.; Smollen, A.; Stevens, E. & Blum, K. 2010. Acute intravenous Synaptamine complex [KB220] TM variant "normalizes" abnormal neurological activity in protracted abstinence of alcohol and opiate patients using quantitative electroencephalographic (QEEG) and neurotransmitter genetic analysis: Pilot two case reports. Postgraduate Medicine 122: 188-213.
68. Miller, N.S. & Gold, M.S. 1994. Dissociation of "conscious desire" (craving) from and relapse in alcohol and cocaine dependence. Annals of Clinical Psychiatry 6 (2): 99-106.
69. Newton, T.F.; Cook, I.A.; Kalechstein, A.D.; Duran, S.; Monroy, F.; Ling, W & Leuchter, A.F. 2003. Quantitative EEG abnormalities in recently abstinent methamphetamine dependent individuals. Clinical Neurophysiology. 114 (3): 410-5.
70. Nikoshkov, A.; Drakenberg, K.; Wang, X.; Horvath, M.C.; Keller, E. & Hurd, Y.L. 2008. Opioid neuropeptide genotypes in relation to heroin abuse: Dopamine tone contributes to reversed mesolimbic proenkephalin expression. Proceedings of the National Academy of Sciences of the USA 105 (2): 786-91.
71. Noble, E.P. 2000. Addiction and its reward process through polymorphisms of the D2 dopamine receptor gene: A review. European Journal of Psychiatry 15 (2): 79-89.
72. Noble, E.P.; Blum, K.; Khalsa, M.E.; Ritchie, T.; Montgomery, A.; Wood, R.C.; Fitch, R.J.; Ozkaragoz, T.; Sheridan, P.J. & Anglin, M.D. 1993. Allelic association of the D2 dopamine receptor gene with cocaine dependence. Drug and Alcohol Dependence 33 (3): 271-85.
73. Noble, E.P.; Blum, K.; Ritchie, T.; Montgomery, A. & Sheridan, P.J. 1991. Allelic association of the D2 dopamine receptor gene with receptor-binding characteristics in alcoholism. Archives of General Psychiatry 48 (7): 648-54.
74. Ooteman, W.; Naassila, M.; Koeter, M.W.; Verheul, R.; Schippers, G.M.; Houchi, H.; Daoust, M. & van den Brink, W. 2009. Predicting the effect of naltrexone and acamprosate in alcohol-dependent patients using genetic indicators. Addiction Biology 14 (3): 328-37.
75. Peng, X.Q.; Xi, Z.X.; Li, X.; Spiller, K.; Li, J.; Chun, L.; Wu, K.M.; Froimowitz, M. & Gardner, E.L. 2010. Is slow-onset long-acting monoamine transport blockade to cocaine asmethadone is to heroin? Implication for anti-addiction medications. Neuropsychopharmacology 35 (13): 2564-78.
76. Peniston, E.G. & Kulkosky, P.J. 1989. Alpha-theta brainwave training and beta-endorphin levels in alcoholics. Alcohol: Clinical and Experimental Research 13 (2): 271-9.
77. Price, S.A. & Tisdale, M.J. 1998. Mechanism of inhibition of a tumor lipid-mobilizing factor by eicosapentaenoic acid. Cancer Research 58 (21): 4827-31.
78. Reid, M.S.; Flammino, F.; Howard, B.; Nilsen, D. & Prichep, L.S. 2006. Topographic imaging of quantitative EEG in response to smoked cocaine self-administration in humans. Neuropsychopharmacology 31 (4): 872-84.
79. Ritchie, T. & Noble, E.P. 2003. Association of seven polymorphisms of the D2 dopamine receptor gene with brain receptor-binding characteristics. Neurochemistry Research 28 (1): 73-82.
80. Roemer, R.A.; Cornwell, A.; Dewart, D.; Jackson, P. & Ercegovac, D.V. 1995. Quantitative electroencephalographic analyses in cocainepreferring polysubstance abusers during abstinence. Psychiatry Research 58 (3): 247-57.
81. Schulden, J.D.; Thomas, Y.F. & Compton, W.M. 2009. Substance abuse in the United States: Findings from recent epidemiologic studies. Current Psychiatry Report 11 (5): 353-9.
82. Sell, L.A.; Simmons, A.; Lemmens, G.M.; Williams, S.C.; Brammer, M. & Strang, J. 1997. Functional magnetic resonance imaging of the acute effect of intravenous heroin administration on visual activation in long-term heroin addicts: Results from a feasibility study. Drug and Alcohol Dependence 49 (1): 55-60.
83. Sokhadze, T.M.; Cannon, R.L. & Trudeau, D. 2008. LEEG biofeedback as a treatment for substance use disorders: Review, rating of efficacy, and recommendations for further research. Applied Psychophysiology and Biofeedback 33 (1): 1-28.
84. Stice, E.; Spoor, S.; Bohon, C. & Small, D.M. 2008. Relation between obesity and blunted striatal response to food is moderated by TaqIA A1 allele. Science 322 (5900): 449-52.
85. Substance Abuse and Mental Health Services Administration, Office of Applied Statistics (SAMHSA). 2009. Results from the 2008 National Survey on Drug Use and Health: National Findings. Washington, DC: U.S. Dept. of Health and Human Services.
86. Tabakoff, B.; Saba, L.; Printz, M.; Flodman, P.; Hodgkinson, C.; Goldman, D.; Koob, G.; Richardson, H.N.; Kechris, K.; Bell, R.L.; Hübner, N.; Heinig, M.; Pravenec, M.; Mangion, J.; Legault, L.; Dongier, M.; Conigrave, K.M.; Whitfield, J.B.; Saunders, J.; Grant, B. & Hoffman, P.L. 2009. WHO/ISBRA Study on State and Trait Markers of Alcoholism. Genetical genomic determinants of alcohol consumption in rats and humans. BMC Biology 27: 7:70.
87. Thanos, P.K.; Michaelides, M; Umegaki, H. & Volkow, N.D. 2008. D2R DNA transfer into the nucleus accumbens attenuates cocaine selfadministration in rats. Synapse 62 (7): 481-86.
88. Thanos, P.K.; Rivera, S.N.; Weaver, K.; Grandy, D.K.; Rubinstein, M.; Umegaki, H.; Wang, G.J.; Hitzemann, R. & Volkow, N. 2005. Dopamine D2R DNA transfer in dopamine D2 receptor-deficient mice: effects on ethanol drinking. Life Science 77 (2): 130-09.
89. Thanos, P.K.; Taintor, N.B.; Rivera, S.N.; Umegaki, H.; Ikari, H.; Roth, G.; Ingram, D.K.; Hitzemann, R.; Fowler, J.S.; Gatley, S.J.; Wang, G.J. & Volkow, N.D. 2004. DRD2 gene transfer into the nucleus accumbens core of the alcohol preferring and nonpreferring rats attenuates alcohol drinking. Alcohol: Clinical and Experimental Research 28 (5): 720-28.
90. Thanos, P.K.; Volkow, N.D.; Freimuth, P.; Umegaki, H.; Ikari, H.; Roth, G.; Ingram, D.K. & Hitzemann, R. 2001. Overexpression of dopamine D2 receptors reduces alcohol self-administration. Journal of Neurochemistry 78 (5): 1094-1103.
91. Trachtenberg, M.C. & Blum, K. 1988. Improvement of cocaine-induced neuromodulator deficits by the neuronutrient Tropamine. Journal of Psychoactive Drugs 20 (3): 315-31.
92. van Diermen, D.; Marston, A.; Bravo, J.; Reist, M.; Carrupt, P.A. & Hostettmann, K. 2009. Monoamine oxidase inhibition by Rhodiola rosea L. roots. Journal of Ethnopharmacology 122 (2): 397-401.
93. Vereczkei, A.; Sasvári-Székely, M. & Barta, C. 2009. The role of genetic variants of the dopaminergic system in heroin dependence. Neuropsychopharmacology Hungarica 11 (2): 95-101.
94. Volkow, N.D.; Valentine, A. & Kulkarni, M. 1988. Radiological and neurological changes in the drug abuse patient: A study with MRI. Journal of Neuroradiology 15 (3): 288-93.
95. Volkow, N.D.; Wang, G.J.; Kollins, S.H.; Wigal, T.L.; Newcorn, J.H.; Telang, F.; Fowler, J.S.; Zhu, W.; Logan, J.; Ma, Y.; Pradhan, K.; Wong, C. & Swanson, J.M. 2009. Evaluating dopamine reward pathway in ADHD: Clinical implications. Journal of the American Medical Association 302 (10): 1084-91.
96. White, M.J.; Lawford, B.R.; Morris, C.P. & Young, R.M. 2009. Interaction between DRD2 C957T polymorphism and an acute psychosocial stressor on reward-related behavioral impulsivity. Behavioral Genetics 39 (3): 285-95.
97. Wurtman, R.J.; Wurtman, J.J.; Regan, M.M.; McDermott, J.M.; Tsay, R.H. & Breu, J.J. 2003. Effects of normal meals rich in carbohydrates or proteins on plasma tryptophan and tyrosine ratios. American Journal of Clinical Nutrition 77 (1): 128-32.
98. Xi, Z.X.; Li, X.; Peng, X.Q.; Li, J.; Chun, L.; Gardner, E.L.; Thomas, A.G.; Slusher, B.S. & Ashby Jr, C.R. 2009. Inhibition of NAALADase by 2-PMPA attenuates cocaine-induced relapse in rats: A NAAG-mGluR2/3-mediated mechanism. Journal of Neurochemistry 112 (2): 564-76.
99. Xu, K.; Lichtermann, D.; Lipsky, R.H.; Franke, P.; Liu, X.; Hu, Y.; Cao, L.; Schwab, S.G.;Wildenauer, D.B.; Bau, C.H.; Ferro, E.; Astor, W.; Finch, T.; Terry, J.; Taubman, J.; Maier, W. & Goldman, D. 2004. Association of specific haplotypes of D2 dopamine receptor gene with vulnerability to heroine dependence in 2 distinct populations. Archives of General Psychiatry 61 (6): 597-606.
100. Yan, Q.S. 2002. Ethanol-induced, nonexocytotic [3H]dopamine release from rat nucleus accumbens slices. Alcohol 27 (2): 127-34.
101. Yang, B. Z., Kranzler, H. R., Zhao, H., Gruen, J. R., Luo, X. & Gelernter, J. 2008. Haplotypic variants in DRD2, ANKK1, TTC12, and NCAM1 are associated with comorbid alcohol and drug dependence. Alcoholism: Clinical & Experimental Research (ACER) 32 (12): 2117-27.
102. Yuan, Y.; Zhu, Z.; Shi, J.; Zou, Z.; Yuan, F.; Liu, Y.; Lee, T.M. & Weng, X. 2009. Gray matter density negatively correlates with duration of heroin use in young lifetime heroin-dependent individuals. Brain Cognition 71 (3): 223-28.
103. Zhou, Q.; Kindlundh, A.M.; Hallberg, M. & Nyberg, F. 2004. The substance P (SP) heptapeptide fragment SP1-7 alters the density of dopamine receptors in rat brain mesocorticolimbic structures during morphine withdrawal. Peptides 25 (11): 1951-57.
104. Zimmer, L.; Vancassel, S.; Cantagrel, S.; Breton, P.; Delamanche, S.; Guilloteau, D.; Durand, G. & Chalon, S. 2002. The dopamine mesocorticolimbic pathway is affected by deficiency in n-3 polyunsaturated fatty acids. American Journal of Clinical Nutrition 75 (4): 662-67.